Medytox "ITC Objection Review Is Just a Routine and General Procedure"

[Asia Economy Reporter Cho Hyun-ui] On the 21st (local time), Medytox stated that the U.S. International Trade Commission (ITC) deciding to review part of the preliminary ruling in the botulinum strain dispute between Daewoong Pharmaceutical and Medytox is "a routine and common procedure in the ITC litigation process" and "cases where the preliminary ruling changes through this are very rare."

According to Medytox on the 22nd, the ITC committee, composed of five commissioners, conducts a review if even one member accepts an objection. The company explained that the ITC committee's review of the preliminary ruling is a routine and common procedure.

Earlier, in July, the ITC issued a preliminary ruling in favor of Medytox and ordered an import ban on Daewoong Pharmaceutical's botulinum toxin 'Nabota' (U.S. name: Jeuveau). In response, Daewoong Pharmaceutical submitted an objection to the preliminary ruling on the 19th of the same month.

The ITC committee's final review result will be confirmed on November 6 (local time), and if approved by the U.S. President two months later, it will be finalized.

A Medytox official said, "Since the ITC administrative law judge made the correct ruling based on scientific evidence and proof, we are confident that the ITC committee will ultimately adopt the preliminary ruling result as is."

This content was produced with the assistance of AI translation services.